Who are the PLWH who might refuse to participate in HIV cure-related clinical trials with treatment interruption?
Résumé
Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
